Linné Yvonne, Rössner Stephan
Obesity Unit, Karolinska University Hospital, Huddinge, Sweden.
Clin Dermatol. 2004 Jul-Aug;22(4):319-24. doi: 10.1016/j.clindermatol.2004.01.008.
Whereas several drugs to treat most other chronic conditions have been developed over the last 30 years, progress in pharmacologic therapy for obesity has been slow. The record of drug treatment for obesity partly explains this phenomenon and is of concern. Several compounds have been withdrawn when severe side effects have been discovered. The lack of scientifically developed safe and effective antiobesity drugs has opened the gates for an enormous number of commercial products that make vast sums of money, but have no scientific evidence backing their efficacy. This pattern is seen in both developed and developing countries. summarizes some of the presently accepted, scientifically evaluated antiobesity drugs. At present, orlistat and sibutramine are the only two major drugs used almost worldwide.
在过去30年里，针对大多数其他慢性疾病已研发出多种药物，然而肥胖症药物治疗的进展却很缓慢。肥胖症药物治疗的记录在一定程度上解释了这一现象，且令人担忧。当发现严重副作用时，几种化合物已被撤市。缺乏科学研发的安全有效的抗肥胖药物，为大量虽能赚取巨额利润但无科学证据支持其疗效的商业产品打开了大门。这种情况在发达国家和发展中国家都存在。总结了一些目前被认可且经过科学评估的抗肥胖药物。目前，奥利司他和西布曲明是全球几乎都在使用的仅有的两种主要药物。
